Cronos Group Inc vs Boston Beer Company Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Boston Beer Company Inc trades at $170.53 (market cap $1.76B). The key difference: Boston Beer Company Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Boston Beer Company Inc for 59 Days on average.
| CRON | SAM | |
|---|---|---|
Market Cap | $1.18B | $1.76B |
Volume | 968,037 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $3.55 | $260.05 |
52-Week Low | $2.30 | $161.08 |
Typical Hold Time | 22 Days | 59 Days |
Enterprise Value | $387.62M | $1.53B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
SAM trades at $168.16, down 1.3% over the past day, with a neutral technical signal and bearish moving averages. The stock has a P/E of 22.66 and P/S of 0.94, indicating moderate valuation. Recent earnings missed expectations in Q1 and Q2 2026, but net income improved to $108.47M in 2025. The company is expanding its product portfolio with new cocktails and coolers, though volume growth remains a challenge.
The outlook is mixed: analyst consensus is a $204.44 price target with a majority hold rating, but negative net income margin and ROE highlight profitability risks. Key opportunities include brand investments and innovation, while risks involve declining volumes and cost pressures in a competitive market.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →